ProCE Banner Activity

Inotuzumab Ozogamicin Plus Reduced-Intensity Chemotherapy Active in Untreated Older Patients With ALL

Slideset Download
Conference Coverage
The combination of inotuzumab ozogamicin with lower-intensity mini-HCVD chemotherapy in older patients with ALL resulted in a high ORR and low early mortality.

Released: December 07, 2016

Expiration: December 06, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Seagen